Bcl-xL promotes metastasis independent of its anti-apoptotic activity

Nature Communications

Volumn 7, Issue , 2016, Pages

  Choi, Soyoung ^a   Chen, Zhengming ^a   Tang, Laura H ^b   Fang, Yuanzhang ^c   Shin, Sandra J ^a   Panarelli, Nicole C ^a   Chen, Yao Tseng ^a   Li, Yi ^c   Jiang, Xuejun ^b   Du, Yi Chieh Nancy ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL XL; TRANSFORMING GROWTH FACTOR BETA; PROTEIN BCL X;

APOPTOSIS; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; GENETIC ENGINEERING; MITOCHONDRION; MUTATION; PROTEIN; RODENT; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; CANCER STEM CELL; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MALE; METASTASIS; MITOCHONDRION; MOUSE; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PROMOTER REGION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; APOPTOSIS; CELL MOTION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO TECHNIQUES; MICE; NEOPLASM METASTASIS;

EID: 84955609337     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10384     Document Type: Article

References (57)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Reed, J. C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17, 2941-2953 (1999).
3. Yin, X. M., Oltvai, Z. N. & Korsmeyer, S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369, 321-323 (1994).
4. Placzek, W. J. et al. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 1, e40 (2010).
5. Davids, M. S. & Letai, A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J. Clin. Oncol. 30, 3127-3135 (2012).
6. Walensky, L. D. From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J. Clin. Oncol. 30, 554-557 (2012).
7. Youle, R. J. & Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59 (2008).
8. Cragg, M. S., Harris, C., Strasser, A. & Scott, C. L. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 9, 321-326 (2009).
9. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5, 876-885 (2005).
10. Michels, J. et al. Functions of BCL-xL at the interface between cell death and metabolism. Int. J. Cell Biol. 2013, 705294 (2013).
11. Hardwick, J. M. & Soane, L. Multiple functions of BCL-2 family proteins. Cold Spring Harb. Perspect. Biol. 5, a008722 (2013).
12. Du, Y. C., Lewis, B. C., Hanahan, D. & Varmus, H. Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biol. 5, e276 (2007).
13. Hager, J. H., Ulanet, D. B., Hennighausen, L. & Hanahan, D. Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancer. PLoS ONE 4, e4455 (2009).
14. Koehler, B. C. et al. Beyond cell deathãantiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. PLoS ONE 8, e76446 (2013).
15. Ho, J. N. et al. Bcl-XL and STAT3 mediate malignant actions of gammairradiation in lung cancer cells. Cancer Sci. 101, 1417-1423 (2010).
16. Weiler, M. et al. BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. Cell Death Differ. 13, 1156-1169 (2006).
17. Espana, L. et al. Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res. Treat. 87, 33-44 (2004).
18. Fernandez, Y., Espana, L., Manas, S., Fabra, A. & Sierra, A. Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance. Cell Death Differ. 7, 350-359 (2000).
19. Martin, S. S. et al. A cytoskeleton-based functional genetic screen identifies BclxL as an enhancer of metastasis, but not primary tumor growth. Oncogene 23, 4641-4645 (2004).
20. Rubio, N., Espana, L., Fernandez, Y., Blanco, J. & Sierra, A. Metastatic behavior of human breast carcinomas overexpressing the Bcl-x(L) gene: a role in dormancy and organospecificity. Lab. Invest. 81, 725-734 (2001).
21. Olopade, O. I. et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 3, 230-237 (1997).
22. Keitel, U. et al. Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget 5, 11778-11791 (2014).
23. Cheng, E. H., Levine, B., Boise, L. H., Thompson, C. B. & Hardwick, J. M. Baxindependent inhibition of apoptosis by Bcl-XL. Nature 379, 554-556 (1996).
24. Sedlak, T. W. et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl Acad. Sci. USA 92, 7834-7838 (1995).
25. Holland, E. C. & Varmus, H. E. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc. Natl Acad. Sci. USA 95, 1218-1223 (1998).
26. Toneff, M. J. et al. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia 12, 718-726 (2010).
27. Du, Y. C., Chou, C. K., Klimstra, D. S. & Varmus, H. Receptor for hyaluronanmediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis. Proc. Natl Acad. Sci. USA 108, 16753-16758 (2011).
28. Evers, B. M. et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 101, 303-311 (1991).
29. Ponomarev, V. et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur. J. Nucl. Med. Mol. Imaging 31, 740-751 (2004).
30. Yasmin, R. et al. Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies. Mediators Inflamm. 2015, 201703 (2015).
31. Massague, J. TGFbeta in cancer. Cell 134, 215-230 (2008).
32. Fiebig, A. A., Zhu, W., Hollerbach, C., Leber, B. & Andrews, D. W. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 6, 213 (2006).
33. Brabletz, T., Jung, A., Spaderna, S., Hlubek, F. & Kirchner, T. Opinion: migrating cancer stem cellsãan integrated concept of malignant tumour progression. Nat. Rev. Cancer 5, 744-749 (2005).
34. Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273 (2009).
35. Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270 (2003).
36. Fillmore, C. M. & Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10, R25 (2008).
37. Boise, L. H. et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608 (1993).
38. Sanchez-Ceja, S. G. et al. Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer 54, 163-168 (2006).
39. Soini, Y. et al. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin. Cancer Res. 5, 3508-3515 (1999).
40. Schulze-Bergkamen, H. et al. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J. Gastroenterol. 14, 3829-3840 (2008).
41. Jin-Song, Y. et al. Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem. 113, 810-814 (2011).
42. Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647-656 (2002).
43. Friess, H. et al. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann. Surg. 228, 780-787 (1998).
44. Yachida, S. et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am. J. Surg. Pathol. 36, 173-184 (2012).
45. Sharma, J. et al. Bcl-XL protein levels determine apoptotic index in pancreatic carcinoma. Pancreas 30, 337-342 (2005).
46. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
47. Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909-916 (2011).
48. Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163-3169 (2012).
49. Lindsten, T. et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 6, 1389-1399 (2000).
50. Wei, M. C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730 (2001).
51. Tang, L. H. et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin. Cancer Res. 18, 4612-4620 (2012).
52. Kang, Y. et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl Acad. Sci. USA 102, 13909-13914 (2005).
53. Du, Y. C., Klimstra, D. S. & Varmus, H. Activation of PyMT in beta cells induces irreversible hyperplasia, but oncogene-dependent acinar cell carcinomas when activated in pancreatic progenitors. PLoS ONE 4, e6932 (2009).
54. Loftus, S. K., Larson, D. M., Watkins-Chow, D., Church, D. M. & Pavan, W. J. Generation of RCAS vectors useful for functional genomic analyses. DNA Res. 8, 221-226 (2001).
55. Ory, D. S., Neugeboren, B. A. & Mulligan, R. C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl Acad. Sci. USA 93, 11400-11406 (1996).
56. Mendez, J. & Stillman, B. Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. Mol. Cell Biol. 20, 8602-8612 (2000).
57. Polo, J. M. et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. 10, 1329-1335 (2004).